| Mohty, Mohamad |
MTX-aGVHD, NCT03371667: To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids |
|
|
| Active, not recruiting | 3 | 102 | Europe | Methotrexate, Placebo | Assistance Publique - Hôpitaux de Paris | Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute, Stem Cell Transplant Complications | 12/24 | 12/24 | | |
NCT03836014 / 2018-004330-15: Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 436 | Europe | Daratumumab/Lenalidomide/Dexamethasone for 24 months, Daratumumab/Lenalidomide/Dexamethasone until progression | Assistance Publique - Hôpitaux de Paris, Inca | Multiple Myeloma in Relapse | 07/26 | 07/26 | | |
FREEDOM, NCT06561854: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone |
|
|
| Recruiting | 3 | 318 | Europe | Dexamethasone, Neofordex | Assistance Publique - Hôpitaux de Paris | Multiple Myeloma, Relapse Multiple Myeloma | 12/28 | 12/28 | | |
MRD-CONFIRM, NCT05203003: Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment. |
|
|
| Recruiting | 3 | 260 | Europe | Assessment of MRD | Assistance Publique - Hôpitaux de Paris | Multiple Myeloma | 04/27 | 12/28 | | |
| Recruiting | 2b | 102 | Europe, Canada, US, RoW | DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan | ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC | Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | 10/24 | 04/25 | | |
NCT02814864: Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy |
|
|
| Recruiting | 2 | 12 | Europe | Mesenchymal Stromal Cell (MSC) injections, Cell therapy | Assistance Publique - Hôpitaux de Paris | Pelvic Radiation Therapy, Radiation-induced Hemorrhagic Cystitis | 04/22 | 04/22 | | |
| Active, not recruiting | 2 | 67 | Europe | Obinutuzumab, gazyva, RO7082859, glofitamab | The Lymphoma Academic Research Organisation | Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma | 01/23 | 03/26 | | |
| Recruiting | 2 | 74 | Europe | Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide | University Hospital, Lille, Janssen Pharmaceutica N.V., Belgium | Multiple Myeloma | 05/25 | 09/30 | | |
HAPLO-EMPTY, NCT05126849: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression |
|
|
| Recruiting | 2 | 31 | Europe | Allogenic transplantation | Assistance Publique - Hôpitaux de Paris | Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation | 01/27 | 01/27 | | |
FLUCLORIC, NCT05917405: Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT |
|
|
| Recruiting | 2 | 302 | Europe | Fludarabine, Busulfan, ATG, Clofarabine | Nantes University Hospital | Acute Myeloid Leukemia in Remission | 09/28 | 09/28 | | |
| Completed | 1/2 | 272 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 07/24 | 11/24 | | |
NCT03309111: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma |
|
|
| Completed | 1 | 81 | Europe, US | ISB 1342 | Ichnos Sciences SA, Glenmark Pharmaceuticals S.A. | Relapsed/Refractory Multiple Myeloma | 12/23 | 12/23 | | |
| Terminated | N/A | 139 | Europe | blood sample analyses | Intergroupe Francophone du Myelome | Multiple Myeloma, Covid19 | 12/22 | 12/22 | | |
| Recruiting | N/A | 204 | Europe | Chemotherapy + follow up, Chemotherapy + ASCT + follow up | Hospices Civils de Lyon | Peripheral T Cell Lymphoma | 04/28 | 04/28 | | |
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
